Inimmune Corporation
Inimmune is a clinical-stage biotech company dedicated to discovering and developing innovative immunotherapies, vaccine adjuvants, and vaccines. Their mission is to harness the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity, and cancer, aiming to make meaningful and lasting positive clinical impacts. With a deep pipeline of clinical and pre-clinical assets and a strong intellectual property position, Inimmune is poised to be a leader in immunotherapy and vaccine adjuvants.
Industries
Nr. of Employees
small (1-50)
Products
Intranasal TLR4 agonist candidate for allergy immunotherapy
An intranasal synthetic TLR4 agonist developed as an allergen-agnostic therapy for allergic rhinitis; completed a Phase I study assessing safety, tolerability, and biomarker responses with results presented at a specialty society meeting.
Systemic lipidated TLR7/8 agonist formulated in a nanoparticle for oncology and adjuvant use
A systemically administered lipidated TLR7/8 agonist formulated in a clinical nanoparticle for oncology immunotherapy and adjuvant applications; advanced into Phase I dose-escalation testing and shown preclinical increases in antigen-presenting cells and CD8 T cell responses.
Mincle-targeting synthetic adjuvant for Th1/Th17-biased responses
A synthetic agonist targeting a C-type lectin receptor developed to induce Th17- and Th1-polarized immune responses for bacterial and fungal vaccine applications; demonstrated protective responses in tuberculosis models and planned for clinical-grade manufacture.
Combination adjuvant systems combining synthetic TLR4 agonists with saponin-based or aluminum-salt components
Adjuvant system approaches pairing a synthetic TLR4 agonist with saponin-based adjuvants or adsorption to aluminum salts to generate synergistic Th1-biased antibody and T cell responses; demonstrated comparable or improved immunogenicity versus existing clinical saponin combinations in preclinical models and advanced to cGMP manufacturing campaigns.
Intranasal TLR4 agonist candidate for allergy immunotherapy
An intranasal synthetic TLR4 agonist developed as an allergen-agnostic therapy for allergic rhinitis; completed a Phase I study assessing safety, tolerability, and biomarker responses with results presented at a specialty society meeting.
Systemic lipidated TLR7/8 agonist formulated in a nanoparticle for oncology and adjuvant use
A systemically administered lipidated TLR7/8 agonist formulated in a clinical nanoparticle for oncology immunotherapy and adjuvant applications; advanced into Phase I dose-escalation testing and shown preclinical increases in antigen-presenting cells and CD8 T cell responses.
Mincle-targeting synthetic adjuvant for Th1/Th17-biased responses
A synthetic agonist targeting a C-type lectin receptor developed to induce Th17- and Th1-polarized immune responses for bacterial and fungal vaccine applications; demonstrated protective responses in tuberculosis models and planned for clinical-grade manufacture.
Combination adjuvant systems combining synthetic TLR4 agonists with saponin-based or aluminum-salt components
Adjuvant system approaches pairing a synthetic TLR4 agonist with saponin-based adjuvants or adsorption to aluminum salts to generate synergistic Th1-biased antibody and T cell responses; demonstrated comparable or improved immunogenicity versus existing clinical saponin combinations in preclinical models and advanced to cGMP manufacturing campaigns.
Services
Co-development and commercialization of adjuvant systems
Collaborative development and commercialization of advanced adjuvant systems combining synthetic innate immune agonists with saponin-based or aluminum-salt adjuvants; includes formulation approaches to improve stability and reduce cold-chain requirements and coordination of partner manufacturing and supply.
AI-assisted lead generation and medicinal chemistry collaboration
Use of generative AI to generate and prioritize novel small-molecule candidates, followed by medicinal chemistry synthesis and biological testing in collaborative research settings.
Clinical development and translational support for early-stage immunotherapies
Execution of early-phase clinical programs including trial design, safety and PK/PD assessment, integrated biomarker strategies, and combination therapy cohort management; includes recent Phase I allergy study with presented results.
Co-development and commercialization of adjuvant systems
Collaborative development and commercialization of advanced adjuvant systems combining synthetic innate immune agonists with saponin-based or aluminum-salt adjuvants; includes formulation approaches to improve stability and reduce cold-chain requirements and coordination of partner manufacturing and supply.
AI-assisted lead generation and medicinal chemistry collaboration
Use of generative AI to generate and prioritize novel small-molecule candidates, followed by medicinal chemistry synthesis and biological testing in collaborative research settings.
Clinical development and translational support for early-stage immunotherapies
Execution of early-phase clinical programs including trial design, safety and PK/PD assessment, integrated biomarker strategies, and combination therapy cohort management; includes recent Phase I allergy study with presented results.
Expertise Areas
- Innate immunomodulator discovery
- Vaccine adjuvant development
- Preclinical in vivo models and challenge studies
- Phase I clinical development and dose-escalation studies
Key Technologies
- TLR agonists (TLR4, TLR7/8)
- C-type lectin receptor agonists
- Nanoparticle delivery platforms (silica, lipidated nanoparticles)
- Saponin-based adjuvants